Loading clinical trials...

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT02507687•AbbVie

View on ClinicalTrials.gov

Summary

This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy (e.g., due to intolerance or nonadherence).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of either open-angle glaucoma or ocular hypertension in each eye that require IOP lowering treatment.
•In the investigator's opinion, patient's IOP is not adequately managed with topical medication for reasons other than medication efficacy (eg, due to intolerance or nonadherence).
•In the investigator's opinion, both eyes can be treated adequately with topical prostamide, prostaglandin, or prostaglandin analog eye drops as the sole therapy if medication was taken as directed, or with SLT monotherapy.

Exclusion Criteria

•History of previous laser trabeculoplasty
•History or evidence of complicated cataract surgery: eg, surgery resulting in complicated lens placement (such as anterior chamber intraocular lens implant \[IOL\], sulcus IOL, aphakia, etc) or intraoperative complications (such as a posterior capsular tear \[with or without vitreous loss\], substantial iris trauma, etc) or history of phakic IOL insertion for refractive error correction
•Intraocular surgery (including cataract surgery) and/or any ocular laser surgery within the 6 months prior to treatment
•Previous use of commercially available Bimatoprost SR; concurrent enrollment in another Allergan Bimatoprost SR study; or previous enrollment in which an implant was received.

Locations (95)

Trinity Research Group /ID# 234598

Dothan, Alabama, United States

Arizona Advanced Eye Research Institute /ID# 234947

Glendale, Arizona, United States

Arizona Glaucoma Specialists /ID# 235066

Phoenix, Arizona, United States

M&M Eye Institute /ID# 235391

Prescott, Arizona, United States

Walman Eye Center /ID# 236054

Sun City, Arizona, United States

California Center for Clin Res /ID# 237412

Arcadia, California, United States

Orange County Ophthalmology /ID# 235995

Garden Grove, California, United States

Speciality Eye Care Medical Group /ID# 236001

Glendale, California, United States

Lugene Eye Institute /ID# 237042

Glendale, California, United States

Lakeside Vision Center /ID# 234971

Irvine, California, United States

Key Dates

Start Date

August 27, 2015

Primary Completion Date

November 24, 2021

Completion Date

May 31, 2023

Last Updated

May 10, 2024

Enrollment

240

ACTUAL participants

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

Bimatoprost SR

DRUG

Sham Bimatoprost SR

DRUG

Selective Laser Trabeculoplasty

PROCEDURE

Sham Selective Laser Trabeculoplasty

PROCEDURE

DSLT for Reducing Medication in Glaucoma

NCT07390890

Primary Open Angle GlaucomaOcular Hypertension

View study

RECRUITINGNA

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

NCT05902871

Primary Open Angle GlaucomaOcular Hypertension+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 10, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Inclusion Criteria

Exclusion Criteria

DSLT for Reducing Medication in Glaucoma

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

Feasibility Clinical Evaluation of the Calibreye System

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT